Anti-opioid effects of neuropeptide FF receptors in the ventral tegmental area

Neuroscience Letters

Volumn 488, Issue 3, 2011, Pages 305-309

  Kersanté, Flavie ^a,b   Wang, Jin Ya ^b   Chen, Jin Chung ^b   Mollereau, Catherine ^a   Zajac, Jean Marie ^a  

^a INSTITUT DE PHARMACOLOGIE ET DE BIOLOGIE STRUCTURALE   (France)

^b CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Dopamine; Microdialysis; Neuropeptide FF; Opioid; Receptor; Serotonin

Indexed keywords

DOPAMINE; MORPHINE; NEUROPEPTIDE FF; NEUROPEPTIDE RECEPTOR; SEROTONIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; MALE; MESOLIMBIC DOPAMINERGIC SYSTEM; MICRODIALYSIS; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; VENTRAL TEGMENTUM;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOPAMINE; MALE; MICRODIALYSIS; MORPHINE; MORPHINE DEPENDENCE; NARCOTICS; NEURONS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NEUROPEPTIDE; SEROTONIN; VENTRAL TEGMENTAL AREA;

EID: 78650836318     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2010.11.052     Document Type: Article

References (35)

1. Altier N., Stewart J. Neuropeptide FF in the VTA blocks the analgesic effects of both intra-VTA morphine and exposure to stress. Brain Res. 1997, 758(1-2):250-254.
2. Attila M., Kurkijarvi U., Kivipelto L., Panula P., Ahtee L. The antiopioid peptide: neuropeptide FF, enhances the effects of acute morphine on the cerebral monoamines in rats. Pharmacol. Res. 1995, 32(5):293-298.
3. Cador M., Marco N., Stinus L., Simonnet G. Interaction between neuropeptide FF and opioids in the ventral tegmental area in the behavioral response to novelty. Neuroscience 2002, 110(2):309-318.
4. Chen J.C., Liang K.W., Huang Y.K., Liang C.S., Chiang Y.C. Significance of glutamate and dopamine neurons in the ventral pallidum in the expression of behavioral sensitization to amphetamine. Life Sci. 2001, 68(9):973-983.
5. Chiang Y.C., Chen P.C., Chen J.C. D(3) dopamine receptors are down-regulated in amphetamine sensitized rats and their putative antagonists modulate the locomotor sensitization to amphetamine. Brain Res. 2003, 972(1-2):159-167.
6. Devine D.P., Leone P., Pocock D., Wise R.A. Differential involvement of ventral tegmental mu, delta and kappa opioid receptors in modulation of basal mesolimbic dopamine release: in vivo microdialysis studies. J. Pharmacol. Exp. Ther. 1993, 266(3):1236-1246.
7. Di Chiara G., Imperato A. Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J. Pharmacol. Exp. Ther. 1988, 244(3):1067-1080.
8. Gelot A., Frances B., Gicquel S., Zajac J.M. Antisense oligonucleotides to human SQA-neuropeptide FF decrease morphine tolerance and dependence in mice. Eur. J. Pharmacol. 1998, 358(3):203-206.
9. Gouarderes C., Puget A., Zajac J.M. Detailed distribution of neuropeptide FF receptors (NPFF1 and NPFF2) in the rat, mouse, octodon, rabbit, guinea pig, and marmoset monkey brains: a comparative autoradiographic study. Synapse 2004, 51(4):249-269.
10. Guiard B.P., El Mansari M., Merali Z., Blier P. Functional interactions between dopamine, serotonin and norepinephrine neurons: an in-vivo electrophysiological study in rats with monoaminergic lesions. Int. J. Neuropsychopharmacol. 2008, 11(5):625-639.
11. Hyman S.E., Malenka R.C., Nestler E.J. Neural mechanisms of addiction: the role of reward-related learning and memory. Annu. Rev. Neurosci. 2006, 29:565-598.
12. Johnson S.W., North R.A. Opioids excite dopamine neurons by hyperpolarization of local interneurons. J. Neurosci. 1992, 12(2):483-488.
13. Jolas T., Aghajanian G.K. Opioids suppress spontaneous and NMDA-induced inhibitory postsynaptic currents in the dorsal raphe nucleus of the rat in vitro. Brain Res. 1997, 755(2):229-245.
14. Kalivas P.W., Duffy P., Eberhardt H. Modulation of A10 dopamine neurons by gamma-aminobutyric acid agonists. J. Pharmacol. Exp. Ther. 1990, 253(2):858-866.
15. Kersante F., Mollereau C., Zajac J.M., Roumy M. Anti-opioid activities of NPFF1 receptors in a SH-SY5Y model. Peptides 2006, 27(5):980-989.
16. Kirouac G.J., Li S., Mabrouk G. GABAergic projection from the ventral tegmental area and substantia nigra to the periaqueductal gray region and the dorsal raphe nucleus. J. Comp. Neurol. 2004, 469(2):170-184.
17. Kotlinska J., Pachuta A., Silberring J. Neuropeptide FF (NPFF) reduces the expression of morphine- but not of ethanol-induced conditioned place preference in rats. Peptides 2007, 28(11):2235-2242.
18. Kotlinska J., Pachuta A., Silberring J. Neuropeptide FF (NPFF) reduces the expression of cocaine-induced conditioned place preference and cocaine-induced sensitization in animals. Peptides 2008, 29(6):933-939.
19. Lake J.R., Hammond M.V., Shaddox R.C., Hunsicker L.M., Yang H.Y., Malin D.H. IgG from neuropeptide FF antiserum reverses morphine tolerance in the rat. Neurosci. Lett. 1991, 132(1):29-32.
20. Lake J.R., Hebert K.M., Payza K., Deshotel K.D., Hausam D.D., Witherspoon W.E., Arcangeli K.A., Malin D.H. Analog of neuropeptide FF attenuates morphine tolerance. Neurosci. Lett. 1992, 146(2):203-206.
21. Malin D.H., Lake J.R., Fowler D.E., Hammond M.V., Brown S.L., Leyva J.E., Prasco P.E., Dougherty T.M. FMRF-NH2-like mammalian peptide precipitates opiate-withdrawal syndrome in the rat. Peptides 1990, 11(2):277-280.
22. Marchand S., Betourne A., Marty V., Daumas S., Halley H., Lassalle J.M., Zajac J.M., Frances B. A neuropeptide FF agonist blocks the acquisition of conditioned place preference to morphine in C57Bl/6J mice. Peptides 2006, 27(5):964-972.
23. Marco N., Stinus L., Allard M., Moal M.L., Simonnet G. NPFF, an anti-opiate peptide, inhibits morphine induced locomotor hyperactivity in rat. Regul. Pept. 1994, 54:181-182.
24. Marco N., Stinus L., Allard M., Le Moal M., Simonnet G. Neuropeptide FLFQRFamide receptors within the ventral mesenchephalon and dopaminergic terminal areas: localization and functional antiopioid involvement. Neuroscience 1995, 64(4):1035-1044.
25. Mollereau C., Roumy M., Zajac J.M. Opioid-modulating peptides: mechanisms of action. Curr. Top. Med. Chem. 2005, 5(3):341-355.
26. Mollereau C., Mazarguil H., Zajac J.M., Roumy M. Neuropeptide FF (NPFF) analogs functionally antagonize opioid activities in NPFF2 receptor-transfected SH-SY5Y neuroblastoma cells. Mol. Pharmacol. 2005, 67(3):965-975.
27. Mouledous L., Frances B., Zajac J.M. Modulation of basal and morphine-induced neuronal activity by a NPFF2 selective agonist measured by c-Fos mapping of the mouse brain. Synapse 2010, 64(9):672-681.
28. Rada P., Mark G.P., Pothos E., Hoebel B.G. Systemic morphine simultaneously decreases extracellular acetylcholine and increases dopamine in the nucleus accumbens of freely moving rats. Neuropharmacology 1991, 30(10):1133-1136.
29. Roumy M., Garnier M., Zajac J.M. Neuropeptide FF receptors 1 and 2 exert an anti-opioid activity in acutely dissociated rat dorsal raphe and periventricular hypothalamic neurones. Neurosci. Lett. 2003, 348(3):159-162.
30. Roumy M., Lorenzo C., Mazeres S., Bouchet S., Zajac J.M., Mollereau C. Physical association between neuropeptide FF and micro-opioid receptors as a possible molecular basis for anti-opioid activity. J. Biol. Chem. 2007, 282(11):8332-8342.
31. Roussin A., Serre F., Gouarderes C., Mazarguil H., Roumy M., Mollereau C., Zajac J.M. Anti-analgesia of a selective NPFF2 agonist depends on opioid activity. Biochem. Biophys. Res. Commun. 2005, 336(1):197-203.
32. Spanagel R., Herz A., Shippenberg T.S. The effects of opioid peptides on dopamine release in the nucleus accumbens: an in vivo microdialysis study. J. Neurochem. 1990, 55(5):1734-1740.
33. Tan P.P., Chen J.C., Li J.Y., Liang K.W., Wong C.H., Huang E.Y. Modulation of naloxone-precipitated morphine withdrawal syndromes in rats by neuropeptide FF analogs. Peptides 1999, 20(10):1211-1217.
34. Tao R., Auerbach S.B. Opioid receptor subtypes differentially modulate serotonin efflux in the rat central nervous system. J. Pharmacol. Exp. Ther. 2002, 303(2):549-556.
35. Tao R., Auerbach S.B. GABAergic and glutamatergic afferents in the dorsal raphe nucleus mediate morphine-induced increases in serotonin efflux in the rat central nervous system. J Pharmacol Exp Ther 2002, 303(2):704-710.